Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXRNASDAQ:OMNASDAQ:POAINASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXRDaxor$9.29+3.2%$8.04$6.55▼$10.00$43.53M-0.132,483 shs4,637 shsOMOutset Medical$18.98-3.0%$16.15$5.85▼$72.60$346.83M2.15128,121 shs1.42 million shsPOAIPredictive Oncology$0.87-3.3%$1.00$0.55▼$3.06$8.04M1.21.93 million shs119,781 shsSURGSurgePays$2.70-3.9%$2.82$1.05▼$3.52$57.36M0.43632,776 shs59,872 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXRDaxor0.00%+2.39%+18.42%+8.04%+1.93%OMOutset Medical0.00%-3.50%+0.31%+94.73%-64.16%POAIPredictive Oncology0.00%-9.09%-18.18%-18.92%-20.35%SURGSurgePays0.00%+4.07%-11.64%+109.70%-20.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AOMOutset Medical1.3818 of 5 stars3.53.00.00.00.00.80.0POAIPredictive Oncology1.4726 of 5 stars3.03.00.00.00.00.00.6SURGSurgePays3.0909 of 5 stars3.55.00.00.02.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXRDaxor 3.00Buy$25.00169.11% UpsideOMOutset Medical 3.00Buy$27.0042.26% UpsidePOAIPredictive Oncology 2.00Hold$3.00244.83% UpsideSURGSurgePays 3.00Buy$9.00233.33% UpsideCurrent Analyst Ratings BreakdownLatest POAI, OM, DXR, and SURG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.75 ➝ $9.005/21/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$14.00 ➝ $21.005/15/2025OMOutset MedicalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $14.004/22/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.50 ➝ $8.753/21/2025OMOutset MedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$15.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXRDaxorN/AN/AN/AN/AN/AN/AOMOutset Medical$113.69M2.96N/AN/A$7.49 per share2.53POAIPredictive Oncology$1.62M4.80N/AN/A($0.03) per share-29.00SURGSurgePays$60.88M0.91N/AN/A$0.76 per share3.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AOMOutset Medical-$127.98M-$29.15N/A∞N/A-98.74%-143.62%-37.50%8/6/2025 (Estimated)POAIPredictive Oncology-$12.66M-$3.05N/AN/AN/A-629.68%-671.29%-132.49%8/12/2025 (Estimated)SURGSurgePays-$45.73M-$2.79N/AN/AN/A-136.37%-206.01%-153.67%8/12/2025 (Estimated)Latest POAI, OM, DXR, and SURG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025POAIPredictive Oncology-$0.09-$0.32-$0.23-$0.34$1.50 million$0.11 million5/13/2025Q1 2025SURGSurgePays-$0.40-$0.38+$0.02-$0.38$9.80 million$10.58 million5/7/2025Q1 2025OMOutset Medical-$0.97-$3.66-$2.69-$3.66$27.81 million$29.75 million3/25/2025Q4 2024SURGSurgePays-$0.27-$0.93-$0.66-$1.02$8.22 million$9.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXRDaxorN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXRDaxorN/AN/AN/AOMOutset Medical0.578.376.74POAIPredictive OncologyN/A0.760.75SURGSurgePays0.241.721.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXRDaxor1.34%OMOutset MedicalN/APOAIPredictive Oncology9.04%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipDXRDaxor59.50%OMOutset Medical2.40%POAIPredictive Oncology3.44%SURGSurgePays30.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXRDaxor374.84 million1.96 millionNot OptionableOMOutset Medical52017.72 million17.30 millionNot OptionablePOAIPredictive Oncology308.93 million8.63 millionNot OptionableSURGSurgePays4020.41 million14.19 millionOptionablePOAI, OM, DXR, and SURG HeadlinesRecent News About These CompaniesSurgePays (NASDAQ:SURG) Price Target Raised to $9.00 at Ascendiant Capital MarketsJune 18 at 1:23 AM | americanbankingnews.comSurgePays (NASDAQ:SURG) Price Target Raised to $9.00June 16, 2025 | marketbeat.comSurgePays to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25June 11, 2025 | prnewswire.comSurgePays, Inc. (NASDAQ:SURG) Sees Significant Decrease in Short InterestJune 4, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?May 31, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Upgraded by Wall Street Zen to Hold RatingMay 24, 2025 | marketbeat.comSurgePays Confirms Directors and Ratifies Accounting FirmMay 20, 2025 | tipranks.comAT&T (NYSE:T) Partners With Carbyne For APEX Continuity Emergency Solution For PSAPsMay 20, 2025 | finance.yahoo.comUS$8.75 - That's What Analysts Think SurgePays, Inc. (NASDAQ:SURG) Is Worth After These ResultsMay 17, 2025 | uk.finance.yahoo.comSurgePays Secures $7M Convertible Note for ExpansionMay 16, 2025 | tipranks.comWhy SurgePays, Inc.’s (SURG) Stock Is Down 19.64%May 15, 2025 | aaii.comQ1 2025 Surgepays Inc Earnings CallMay 15, 2025 | uk.finance.yahoo.comSurgePays, Inc. (SURG) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comSurgePays, Inc. (SURG) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comSurgePays Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comSurgePays Announces $7 Million Debt Financing to Accelerate GrowthMay 13, 2025 | prnewswire.comSurgePays to Host First Quarter 2025 Financial Results Conference Call on Tuesday, May 13thMay 6, 2025 | prnewswire.comEarnings Preview: SurgePays, Inc. (SURG) Q1 Earnings Expected to DeclineMay 5, 2025 | zacks.comPOS Fintech SurgePays Launches on AT&TApril 28, 2025 | crowdfundinsider.comSurgePays Launches Nationwide on AT&T Network with 250,000 SIMs ShippedApril 24, 2025 | prnewswire.comSurgePays Promotes Derron Winfrey to President, Sales and OperationsApril 23, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong RecoveriesPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryPOAI, OM, DXR, and SURG Company DescriptionsDaxor NASDAQ:DXR$9.29 +0.29 (+3.22%) As of 12:12 PM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Outset Medical NASDAQ:OM$18.98 -0.59 (-3.01%) Closing price 04:00 PM EasternExtended Trading$18.99 +0.01 (+0.05%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.Predictive Oncology NASDAQ:POAI$0.87 -0.03 (-3.33%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.03 (+2.87%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.SurgePays NASDAQ:SURG$2.70 -0.11 (-3.91%) Closing price 04:00 PM EasternExtended Trading$2.71 +0.01 (+0.37%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
